Dr Reddy's Laboratories: Number of Employees 2010-2024 | RDY

Interactive chart of Dr Reddy's Laboratories (RDY) annual worldwide employee count from 2010 to 2024.
  • Dr Reddy's Laboratories total number of employees in 2024 was 27,048, a 4.58% increase from 2023.
  • Dr Reddy's Laboratories total number of employees in 2023 was 25,863, a 4.31% increase from 2022.
  • Dr Reddy's Laboratories total number of employees in 2022 was 24,795, a 9.04% increase from 2021.
  • Dr Reddy's Laboratories total number of employees in 2021 was 22,739, a 5.03% increase from 2020.
Dr Reddy's Laboratories Annual Employee Count
2024 27,048
2023 25,863
2022 24,795
2021 22,739
2020 21,650
2019 21,966
2018 23,524
2017 22,671
2016 22,175
2015 20,373
2014 18,421
2013 16,617
2012 15,200
2011 14,923
2010
2009 11,228
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $11.978B $3.350B
Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company engaged in providing affordable and innovative medicines since 1984. The company markets its products in countries like the U.S., the UK, Germany, India, Russia, Venezuela, Romania and South Africa. Dr. Reddy's operates through three segments: Global Generics comprising unbranded prescription drugs along with over-the-counter drugs. It includes the operations of the company's biologics business. Pharmaceutical Services & Active Ingredients (PSAI) comprising active pharmaceutical ingredients (API) and custom pharmaceutical services. Proprietary Products and Others involving the new chemical entities, the differentiated formulations business and a dermatology specialty business. The company has a strategic partnership with Glaxo to market selected products across emerging markets outside India.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.044B 6.25
BridgeBio Pharma (BBIO) United States $4.260B 0.00
Bausch Health Cos (BHC) Canada $3.012B 2.18
Amphastar Pharmaceuticals (AMPH) United States $2.097B 12.61
Supernus Pharmaceuticals (SUPN) United States $1.962B 26.71
Taysha Gene Therapies (TSHA) United States $0.434B 30.29
Personalis (PSNL) United States $0.261B 0.00
Assembly Biosciences (ASMB) United States $0.098B 0.00
Sol-Gel Technologies (SLGL) Israel $0.012B 0.00
Evoke Pharma (EVOK) United States $0.007B 0.00
Teligent (TLGT) United States $0.000B 0.00